Author/Editor		Uršič-Vrščaj, M; Kovačič, J; Bebar, S; Djurišič, A; Fras, PA; Robič, V
Title		Endometrial and other primary cancers after tamoxifen treatment of breast cancer - results of retrospective cohort study
Type		članek
Source		Eur J Obstet Gynecol Reprod Biol
Vol. and No.		Letnik 95, št. 1
Publication year		2001
Volume		str. 105-10
Language		eng
Abstract		Objectives: The aim of the retrospective cohort study was to evaluate the relationship between the influence of tamoxifen on the development of endometrial and other second primary cancers in the patients with invasive breast cancer. Study Design: A cohort of 630 women diagnosed with breast cancer from 1987 to 1994 was selected from a population-based registry; 440 patients were treated with tamoxifen and 190 patients without it. The observation period was 8.5 years (range 5-12 years). The data were analysed by the relative risk (RR) calculation at a confidence interval (CI) of 95%, using a Mantel-Haenszel chi(2)-test and Fisher's p-test to evaluate statistical significance. Results: There were no statistically significant differences between the group of breast cancer patients treated with tamoxifen and without it as regards the age at the breast cancer diagnosis, family medical histories, body mass, age at menopause, fertility, diabetes, hormone replacement therapy and oestrogen-hormone replacement therapy. In 41/440 (9.3%) tamoxifen-treated patients and in 8/190 (4.2%) non-users of tamoxifen, diagnostic curettage was performed due to benign endometrial changes and endometrial cancer (EC). The difference in the proportions of patients with diagnostic curettage in both group was statistically significant (chi(2)=4.45, p=0.03). In the group of patients treated with tamoxifen, with the median treatment duration of 40 months (range 1-97 months) and in the group of patients without tamoxifen, EC was diagnosed in 11 and in two patients, respectively. The evaluated RR was 2.38 (0.53-10.61, 95% CI). (Abstract truncated at 2000 characters).
Descriptors		BREAST NEOPLASMS TAMOXIFEN ENDOMETRIAL NEOPLASMS NEOPLASMS, SECOND PRIMARY COHORT STUDIES RETROSPECTIVE STUDIES AGE FACTORS